Closed Bladder, Kidney and Prostate trials
Trials closed to recruitment
TROG 15.01 (SPARK) - this trial is testing the use of Kilvoltage Intrafraction Monitoring (KIM) in prostate cancer patients being treated with Stereotactic Prostate Adaptive Radiotherapy. The researchers expect this trial to result in better targeted prostate cancer patient outcomes with lower toxicity.
Primary sponsor: University of Sydney
Collaborating groups: TROG
ANZUP 1303 (ENZARAD) - the study will compare the effectiveness of standard deprivation therapy and radiation therapy combined either with enzalutamide or currently available antiandrogen drugs for improving the survival in men with localised prostate cancer at high risk of recurrence.
Primary sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Collaborating group: TROG (TROG 14.01)
TROG 08.03 (RAVES) - the aim of the study is to compare in patients who have had a prostatectomy whether treatment with active surveillance and early salvage radiotherapy is as effective as immediate radiotherapy.
Primary sponsor: TROG
Collaborating groups: Urological Society of Australia & New Zealand (USANZ); Australian & New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Psycho-Oncology Co-operative Research Group (PoCoG)
TROG 08.01 (PROFIT) - this prostate trial was designed to determine whether an 8-week course of radiation can be compressed safely and with similar efficacy into a 4-week course.
Primary sponsor: Ontario Clinical Oncology Group (OCOG)
Collaborating groups: TROG; Canadian Institutes of Health Research (CIHR)
TROG 03.04 (RADAR) - six months of hormone treatment improves the results of radiotherapy for men with early prostate cancer. The aim of this trial was to determine if adding another 12 months of hormone treatment after radiotherapy was even better.
Primary Sponsor: TROG
TROG 02.03 - the purpose of this study was to define the optimal management of patients with localised transitional cell carcinoma (TCC) of the bladder by evaluating whether chemoradiation is better to radiotherapy alone.
Primary sponsor: TROG
Collaborating group: Urological Society of Australasia (USA)
TROG 10.01 (BOLART) - this study investigated whether a new method of giving radiation therapy for bladder cancer by adapting to the size of the bladder at each treatment could be done consistently in a number of different radiation oncology departments in Australia and New Zealand.
TROG 03.06 (TOAD) - this trial was developed to determine if it is better to start hormone treatment straight away or to wait and start hormone treatment only after prostate cancer begins to cause problems.
TROG 99.06 - Phase I/II Study of Trans-Urethral Resection Followed by Modified Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder
TROG 98.03 - Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy
TROG 97.01 - A Phase II Study of Trans-Urethral Resection Followed by Synchronous Chemo-Radiation in the Definitive Management of Localised Invasive TCC of the Urinary Bladder
TROG 96.01 - A Randomised Trial Investigating the Effectiveness of Different Durations of Maximal Androgen Deprivation Prior to and During Definitive Radiation Therapy for Locally Advanced Carcinoma of the Prostate
TROG 95.03 - Phase III Double Blind Study of Pentosan Polysulphate Sodium (PPS) in the treatment of Late (Chronic) Radiation Proctitis